AngioDynamics, Inc.
AngioDynamics, Inc. (ANGO) Financial Performance & Income Statement Overview
Access detailed quarterly and annual financial reports for AngioDynamics, Inc. (ANGO), covering cash flow, earnings, and balance sheets.
AngioDynamics, Inc. (ANGO) Income Statement & Financial Overview
Access detailed annual and quarterly income data for AngioDynamics, Inc. ANGO financial performance.
| Metric | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|
| Revenue | $80.16M | $72.004M | $72.84M | $67.49M |
| Cost of Revenue | $37.94M | $33.15M | $32.94M | $30.77M |
| Gross Profit | $42.22M | $38.86M | $39.91M | $36.72M |
| Gross Profit Ratio | $0.53 | $0.54 | $0.55 | $0.54 |
| R&D Expenses | $6.59M | $6.91M | $6.43M | $6.29M |
| SG&A Expenses | $36.67M | $35.99M | $35.98M | $36.58M |
| Operating Expenses | $43.26M | $42.91M | $42.41M | $49.82M |
| Total Costs & Expenses | $81.20M | $81.98M | $83.94M | $80.59M |
| Interest Income | $0.00 | $135000.00 | $234000.00 | $606000.00 |
| Interest Expense | $0.00 | $0.00 | $0.00 | $0.00 |
| Depreciation & Amortization | $0.00 | $6.32M | $6.86M | $6.79M |
| EBITDA | -$1.04M | -$329000.00 | $1.79M | -$1.93M |
| EBITDA Ratio | -$0.01 | -$0.005 | $0.02 | -$0.03 |
| Operating Income | -$1.04M | -$4.05M | -$2.51M | -$13.10M |
| Operating Income Ratio | -$0.01 | -$0.06 | -$0.03 | -$0.19 |
| Other Income/Expenses (Net) | -$5.07M | $5.57M | $246000.00 | $433000.00 |
| Income Before Tax | -$6.11M | -$4.41M | -$10.85M | -$12.66M |
| Income Before Tax Ratio | -$0.08 | -$0.06 | -$0.15 | -$0.19 |
| Income Tax Expense | -$60000.00 | -$2000.00 | -$110000.00 | $133000.00 |
| Net Income | -$6.05M | -$4.41M | -$10.74M | -$12.80M |
| Net Income Ratio | -$0.08 | -$0.06 | -$0.15 | -$0.19 |
| EPS | -$0.15 | -$0.11 | -$0.26 | -$0.31 |
| Diluted EPS | -$0.15 | -$0.11 | -$0.26 | -$0.31 |
| Weighted Avg Shares Outstanding | $40.98M | $40.85M | $40.92M | $40.65M |
| Weighted Avg Shares Outstanding (Diluted) | $40.98M | $40.85M | $40.92M | $40.65M |
Financial performance has remained strong, with revenue growing from $67.49M in Q1 2025 to $80.16M in Q4 2025. Gross profit continued to perform well, with margins at 53% in the latest quarter. Operating income reached -$1.04M in Q4 2025, holding a steady -1% margin. While R&D and SG&A expenses fluctuated, EBITDA remained robust at -$1.04M. Net income dropped to -$6.05M, keeping EPS at -$0.15. With disciplined cost control and operational efficiency, the company supported consistent profitability, reflecting its ability to deliver stable shareholder value.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan